Mice expressing human CR1/CD35 have an enhanced humoral immune response to T-dependent antigens but fail to correct the effect of premature human CR2 expression

Immunobiology

Volumn 217, Issue 2, 2012, Pages 147-157

  Pappworth, Isabel Y ^a   Hayes, Christine ^a   Dimmick, Jason ^b   Morgan, B Paul ^b   Holers, V Michael ^c   Marchbank, Kevin J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Anergy; B cell; Complement receptor; Humoral immune response; Marginal zone

Indexed keywords

COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C3D RECEPTOR; T LYMPHOCYTE ANTIGEN;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ARTICLE; B LYMPHOCYTE; CELL FUNCTION; CELL MATURATION; CELL SURFACE; COMPLEMENT INHIBITION; CONTROLLED STUDY; ERYTHROCYTE; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODY FORMATION; B-LYMPHOCYTES; ERYTHROCYTES; GERMINAL CENTER; IMMUNITY, HUMORAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RECEPTORS, COMPLEMENT 3B; SIGNAL TRANSDUCTION; TRANSGENES;

EID: 84855254299     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2011.06.001     Document Type: Article

References (60)

1. Ahearn J.M., Fischer M.B., Croix D., Goerg S., Ma M., Xia J., Zhou X., Howard R.G., Rothstein T.L., Carroll M.C. Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen. Immunity 1996, 4(3):251-262.
2. Alexander J.J., Hack B.K., Cunningham P.N., Quigg R.J. A protein with characteristics of factor H is present on rodent platelets and functions as the immune adherence receptor. J. Biol. Chem. 2001, 276(34):32129-32135.
3. Alexander J.J., Hack B.K., Jacob A., Chang A., Haas M., Finberg R.W., Quigg R.J. Abnormal immune complex processing and spontaneous glomerulonephritis in complement factor H-deficient mice with human complement receptor 1 on erythrocytes. J. Immunol. 2010, 185(6):3759-3767.
4. Alexander J.J., Quigg R.J. The simple design of complement factor H: looks can be deceiving. Mol. Immunol. 2007, 44(1-3):123-132.
5. Bacle F., Haeffner-Cavaillon N., Laude M., Couturier C., Kazatchkine M.D. Induction of IL-1 release through stimulation of the C3b/C4b complement receptor type one (CR1, CD35) on human monocytes. J. Immunol. 1990, 144(1):147-152.
6. Batista F.D., Harwood N.E. The who, how and where of antigen presentation to B cells. Nat. Rev. Immunol. 2009, 9(1):15-27.
7. Birrell L., Kulik L., Morgan B.P., Holers V.M., Marchbank K.J. B cells from mice prematurely expressing human complement receptor type 2 are unresponsive to T-dependent antigens. J. Immunol. 2005, 174(11):6974-6982.
8. Bradbury L.E., Kansas G.S., Levy S., Evans R.L., Tedder T.F. The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J. Immunol. 1992, 149(9):2841-2850.
9. Cyster J.G. B cell follicles and antigen encounters of the third kind. Nat. Immunol. 2010, 11(11):989-996.
10. Dempsey P.W., Allison M.E., Akkaraju S., Goodnow C.C., Fearon D.T. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 1996, 271(5247):348-350.
11. Fang Y., Xu C., Fu Y.X., Holers V.M., Molina H. Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response. J. Immunol. 1998, 160(11):5273-5279.
12. Fearon D.T. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J. Exp. Med. 1980, 152(1):20-30.
13. Guthridge J.M., Young K., Gipson M.G., Sarrias M.R., Szakonyi G., Chen X.S., Malaspina A., Donoghue E., James J.A., Lambris J.D., Moir S.A., Perkins S.J., Holers V.M. Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface. J. Immunol. 2001, 167(10):5758-5766.
14. Haas K.M., Hasegawa M., Steeber D.A., Poe J.C., Zabel M.D., Bock C.B., Karp D.R., Briles D.E., Weis J.H., Tedder T.F. Complement receptors CD21/35 link innate and protective immunity during Streptococcus pneumoniae infection by regulating IgG3 antibody responses. Immunity 2002, 17(6):713-723.
15. Harwood N.E., Batista F.D. The antigen expressway: follicular conduits carry antigen to B cells. Immunity 2009, 30(2):177-179.
16. Hivroz C., Fischer E., Kazatchkine M.D., Grillot-Courvalin C. Differential effects of the stimulation of complement receptors CR1 (CD35) and CR2 (CD21) on cell proliferation and intracellular Ca2+ mobilization of chronic lymphocytic leukemia B cells. J. Immunol. 1991, 146(6):1766-1772.
17. Holers V.M., Kinoshita T., Molina H. The evolution of mouse and human complement C3-binding proteins: divergence of form but conservation of function. Immunol. Today 1992, 13(6):231-236.
18. Holers V.M., Seya T., Brown E., O'Shea J.J., Atkinson J.P. Structural and functional studies on the human C3b/C4b receptor (CR1) purified by affinity chromatography using a monoclonal antibody. Complement 1986, 3(2):63-78.
19. Huber V.C., McKeon R.M., Brackin M.N., Miller L.A., Keating R., Brown S.A., Makarova N., Perez D.R., Macdonald G.H., McCullers J.A. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin. Vaccine Immunol. 2006, 13(9):981-990.
20. Iking-Konert C., Stocks S., Weinsberg F., Engelbrecht R., Bleck E., Perniok A., Fischer-Betz R., Pincus S., Nardone L., Schneider M. First clinical trials of a new heteropolymer technology agent in normal healthy volunteers and patients with systemic lupus erythematosus: safety and proof of principle of the antigen-heteropolymer ETI-104. Ann. Rheum. Dis. 2004, 63(9):1104-1112.
21. Jacobson A.C., Weis J.J., Weis J.H. Complement receptors 1 and 2 influence the immune environment in a B cell receptor-independent manner. J. Immunol. 2008, 180(7):5057-5066.
22. Janeway, C.A., Travers Jr., P., Walport, M., et al. 2001. Immunobiology: The Immune System in Health and Disease, fifth ed., Garland.
23. Jozsi M., Prechl J., Bajtay Z., Erdei A. Complement receptor type 1 (CD35) mediates inhibitory signals in human B lymphocytes. J. Immunol. 2002, 168(6):2782-2788.
24. Kai S., Fujita T., Gigli I., Nussenzweig V. Mouse C3b/C4b inactivator: purification and properties. J. Immunol. 1980, 125(6):2409-2415.
25. Kaya Z., Tretter T., Schlichting J., Leuschner F., Afanasyeva M., Katus H.A., Rose N.R. Complement receptors regulate lipopolysaccharide-induced T-cell stimulation. Immunology 2005, 114(4):493-498.
26. Kinoshita T., Takeda J., Hong K., Kozono H., Sakai H., Inoue K. Monoclonal antibodies to mouse complement receptor type 1 (CR1), their use in a distribution study showing that mouse erythrocytes and platelets are CR1-negative. J. Immunol. 1988, 140(9):3066-3072.
27. Krych-Goldberg M., Atkinson J.P. Structure-function relationships of complement receptor type 1. Immunol. Rev. 2001, 180:112-122.
28. Kulik L., Chen K., Huber B.T., Holers V.M. Human complement receptor type 2 (CR2/CD21) transgenic mice provide an in vivo model to study immunoregulatory effects of receptor antagonists. Mol. Immunol. 2011, 48(6-7):883-894.
29. Kulik L., Marchbank K.J., Lyubchenko T., Kuhn K.A., Liubchenko G.A., Haluszczak C., Gibson M.G., Boackle S.A., Holers V.M. Intrinsic B cell hypo-responsiveness in mice prematurely expressing human CR2/CD21 during B cell development. Eur. J. Immunol. 2007, 37(3):623-633.
30. Kurtz C.B., O'Toole E., Christensen S.M., Weis J.H. The murine complement receptor gene family. IV. Alternative splicing of Cr2 gene transcripts predicts two distinct gene products that share homologous domains with both human CR2 and CR1. J. Immunol. 1990, 144(9):3581-3591.
31. Law S.K., Fearon D.T., Levine R.P. Action of the C3b-inactivator on the cell-bound C3b. J. Immunol. 1979, 122(3):759-765.
32. Lee Y., Haas K.M., Gor D.O., Ding X., Karp D.R., Greenspan N.S., Poe J.C., Tedder T.F. Complement component C3d-antigen complexes can either augment or inhibit B lymphocyte activation and humoral immunity in mice depending on the degree of CD21/CD19 complex engagement. J. Immunol. 2005, 175(12):8011-8023.
33. Li J., Wang J.P., Ghiran I., Cerny A., Szalai A.J., Briles D.E., Finberg R.W. Complement receptor 1 expression on mouse erythrocytes mediates clearance of Streptococcus pneumoniae by immune adherence. Infect. Immun. 2010, 78(7):3129-3135.
34. Marchbank K.J., Kulik L., Gipson M.G., Morgan B.P., Holers V.M. Expression of human complement receptor type 2 (CD21) in mice during early B cell development results in a reduction in mature B cells and hypogammaglobulinemia. J. Immunol. 2002, 169(7):3526-3535.
35. Marchbank K.J., Watson C.C., Ritsema D.F., Holers V.M. Expression of human complement receptor 2 (CR2, CD21) in Cr2-/- mice restores humoral immune function. J. Immunol. 2000, 165(5):2354-2361.
36. Matsumoto A.K., Kopicky-Burd J., Carter R.H., Tuveson D.A., Tedder T.F., Fearon D.T. Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19. J. Exp. Med. 1991, 173(1):55-64.
37. Matsumoto A.K., Martin D.R., Carter R.H., Klickstein L.B., Ahearn J.M., Fearon D.T. Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B lymphocytes. J. Exp. Med. 1993, 178(4):1407-1417.
38. Molina H., Holers V.M., Li B., Fung Y., Mariathasan S., Goellner J., Strauss-Schoenberger J., Karr R.W., Chaplin D.D. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc. Natl. Acad. Sci. U.S.A. 1996, 93(8):3357-3361.
39. Molina H., Kinoshita T., Inoue K., Carel J.C., Holers V.M. A molecular and immunochemical characterization of mouse CR2, Evidence for a single gene model of mouse complement receptors 1 and 2. J. Immunol. 1990, 145(9):2974-2983.
40. Mongini P.K., Vilensky M.A., Highet P.F., Inman J.K. The affinity threshold for human B cell activation via the antigen receptor complex is reduced upon co-ligation of the antigen receptor with CD21 (CR2). J. Immunol. 1997, 159(8):3782-3791.
41. Mulligan M.S., Yeh C.G., Rudolph A.R., Ward P.A. Protective effects of soluble CR1 in complement- and neutrophil-mediated tissue injury. J. Immunol. 1992, 148(5):1479-1485.
42. Pappworth I.Y., Kulik L., Haluszczak C., Reuter J.W., Holers V.M., Marchbank K.J. Increased B cell deletion and significantly reduced auto-antibody titre due to premature expression of human complement receptor 2 (CR2, CD21). Mol. Immunol. 2009.
43. Pemberton M., Anderson G., Vetvicka V., Justus D.E., Ross G.D. Microvascular effects of complement blockade with soluble recombinant CR1 on ischemia/reperfusion injury of skeletal muscle. J. Immunol. 1993, 150(11):5104-5113.
44. Phan T.G., Grigorova I., Okada T., Cyster J.G. Subcapsular encounter and complement-dependent transport of immune complexes by lymph node B cells. Nat. Immunol. 2007, 8(9):992-1000.
45. Prodeus A.P., Goerg S., Shen L.M., Pozdnyakova O.O., Chu L., Alicot E.M., Goodnow C.C., Carroll M.C. A critical role for complement in maintenance of self-tolerance. Immunity 1998, 9(5):721-731.
46. Ramaglia V., Wolterman R., de Kok M., Vigar M.A., Wagenaar-Bos I., King R.H., Morgan B.P., Baas F Soluble complement receptor 1 protects the peripheral nerve from early axon loss after injury. Am. J. Pathol. 2008, 172(4):1043-1052.
47. Smith R.A., Young J., Weis J.J., Weis J.H. Expression of the mouse fragilis gene products in immune cells and association with receptor signaling complexes. Genes Immun. 2006, 7(2):113-121.
48. Takahashi K., Kozono Y., Waldschmidt T.J., Berthiaume D., Quigg R.J., Baron A., Holers V.M. Mouse complement receptors type 1 (CR1;CD35) and type 2 (CR2;CD21): expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice. J. Immunol. 1997, 159(3):1557-1569.
49. Takehara H.A., Perini A., da Silva M.H., Mota I. Trypanosoma cruzi: role of different antibody classes in protection against infection in the mouse. Exp. Parasitol. 1981, 52(1):137-146.
50. Thieblemont N., Haeffner-Cavaillon N., Ledur A., L'Age-Stehr J., Ziegler-Heitbrock H.W., Kazatchkine M.D. CR1 (CD35) and CR3 (CD11b/CD18) mediate infection of human monocytes and monocytic cell lines with complement-opsonized HIV independently of CD4. Clin. Exp. Immunol. 1993, 92(1):106-113.
51. Tsokos G.C., Berger M., Balow J.E. Modulation of human B cell immunoglobulin secretion by the C3b component of complement. J. Immunol. 1984, 132(2):622-626.
52. Tuveson D.A., Ahearn J.M., Matsumoto A.K., Fearon D.T. Molecular interactions of complement receptors on B lymphocytes: a CR1/CR2 complex distinct from the CR2/CD19 complex. J. Exp. Med. 1991, 173(5):1083-1089.
53. Twohig J., Kulik L., Haluszczak C., Reuter J., Rossbach A., Bull M., Holers V.M., Marchbank K.J. Defective B, cell ontogeny and immune response in human complement receptor 2 (CR2, CD21) transgenic mice is partially recovered in the absence of C3. Mol. Immunol. 2007, 44(13):3434-3444.
54. Twohig J.P., Pappworth I.Y., Sivasankar B., Kulik L., Bull M., Holers V.M., Wang E.C., Marchbank K.J. Defective B, cell ontogeny and humoral immune response in mice prematurely expressing human complement receptor 2 (CR2, CD21) is similar to that seen in aging wild type mice. Mol. Immunol. 2009, 46(10):2002-2013.
55. Voynova E., Tchorbanov A., Prechl J., Nikolova M., Baleva M., Erdei A., Vassilev T. An antibody-based construct carrying DNA-mimotope and targeting CR1(CD35) selectively suppresses human autoreactive B-lymphocytes. Immunol. Lett. 2008, 116(2):168-173.
56. Weisman H.F., Bartow T., Leppo M.K., Boyle M.P., Marsh H.C., Carson G.R., Roux K.H., Weisfeldt M.L., Fearon D.T. Recombinant soluble CR1 suppressed complement activation, inflammation, and necrosis associated with reperfusion of ischemic myocardium. Trans. Assoc. Am. Phys. 1990, 103:64-72.
57. Weisman H.F., Bartow T., Leppo M.K., Marsh H.C., Carson G.R., Concino M.F., Boyle M.P., Roux K.H., Weisfeldt M.L., Fearon D.T. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990, 249(4965):146-151.
58. Whipple E.C., Shanahan R.S., Ditto A.H., Taylor R.P., Lindorfer M.A. Analyses of the in vivo trafficking of stoichiometric doses of an anti-complement receptor 1/2 monoclonal antibody infused intravenously in mice. J. Immunol. 2004, 173(4):2297-2306.
59. Wu X., Jiang N., Deppong C., Singh J., Dolecki G., Mao D., Morel L., Molina H.D. A role for the Cr2 gene in modifying autoantibody production in systemic lupus erythematosus. J. Immunol. 2002, 169(3):1587-1592.
60. Wu X., Jiang N., Fang Y.F., Xu C., Mao D., Singh J., Fu Y.X., Molina H. Impaired affinity maturation in Cr2-/- mice is rescued by adjuvants without improvement in germinal center development. J. Immunol. 2000, 165(6):3119-3127.